DIN 02478293 — SOLIQUA 33 MCG; 100 UNIT
SOLIQUA is a solution of Insulin Glargine / Lixisenatide marketed by SANOFI-AVENTIS CANADA INC. The full Insulin Glargine / Lixisenatide monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.
- DIN
- 02478293
- Brand name
- SOLIQUA
- Active ingredient
- Insulin Glargine / Lixisenatide
- Strength
- 33 MCG; 100 UNIT
- Dosage form
- SOLUTION
- Route
- SUBCUTANEOUS
- Manufacturer
- SANOFI-AVENTIS CANADA INC
- Health Canada status
- MARKETED
- Drug class
- Fixed-ratio combination of a basal insulin analogue and a GLP-1 receptor agonist
Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.